Spruce Biosciences, Inc. (SPRB)
SPRB Stock Price Chart
Explore Spruce Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze SPRB price movements and trends.
SPRB Company Profile
Discover essential business fundamentals and corporate details for Spruce Biosciences, Inc. (SPRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Oct 2020
Employees
20.00
CEO
Javier Szwarcberg
Description
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Financial Timeline
Browse a chronological timeline of Spruce Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$5.79.
Earnings released on 13 May 2026
EPS came in at -$8.94 falling short of the estimated -$7.32 by -22.13%.
Earnings released on 9 Mar 2026
EPS came in at -$9.58 surpassing the estimated -$12.87 by +25.56%.
Earnings released on 10 Nov 2025
EPS came in at -$14.58 surpassing the estimated -$15.56 by +6.30%.
Earnings released on 14 Aug 2025
EPS came in at -$3.50 surpassing the estimated -$18.05 by +80.61%.
Stock split effective on 5 Aug 2025
Shares were split 1 : 75 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 May 2025
EPS came in at -$24.06 falling short of the estimated -$18.80 by -27.98%.
Earnings released on 2 Apr 2025
EPS came in at -$0.23 surpassing the estimated -$0.24 by +4.17%, while revenue for the quarter reached $697.00k , missing expectations by -21.24%.
Earnings released on 11 Nov 2024
EPS came in at -$15.79 surpassing the estimated -$20.30 by +22.22%, while revenue for the quarter reached $602.00k , beating expectations by +80.60%.
Earnings released on 12 Aug 2024
EPS came in at -$16.54 surpassing the estimated -$24.81 by +33.33%, while revenue for the quarter reached $1.61m , beating expectations by +8.05%.
Earnings released on 13 May 2024
EPS came in at -$21.05 surpassing the estimated -$24.06 by +12.51%, while revenue for the quarter reached $2.00m , beating expectations by +72.59%.
Earnings released on 13 Mar 2024
EPS came in at -$17.29 surpassing the estimated -$30.83 by +43.92%, while revenue for the quarter reached $2.89m , beating expectations by +106.21%.
Earnings released on 13 Nov 2023
EPS came in at -$22.56 surpassing the estimated -$25.56 by +11.74%, while revenue for the quarter reached $3.07m , beating expectations by +136.38%.
Earnings released on 14 Aug 2023
EPS came in at -$24.06 surpassing the estimated -$27.82 by +13.52%, while revenue for the quarter reached $2.17m , beating expectations by +164.02%.
Earnings released on 15 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $1.98m , missing expectations by -68.54%.
Earnings released on 16 Mar 2023
EPS came in at -$35.34 surpassing the estimated -$41.35 by +14.53%.
Earnings released on 10 Nov 2022
EPS came in at -$36.09 surpassing the estimated -$40.60 by +11.11%.
Earnings released on 10 Aug 2022
EPS came in at -$38.35 surpassing the estimated -$40.60 by +5.54%.
Earnings released on 11 May 2022
EPS came in at -$37.59 falling short of the estimated -$33.83 by -11.11%.
Earnings released on 14 Mar 2022
EPS came in at -$29.32 surpassing the estimated -$42.86 by +31.59%.
Earnings released on 15 Nov 2021
EPS came in at -$36.84 surpassing the estimated -$42.86 by +14.05%.
Earnings released on 10 Aug 2021
EPS came in at -$37.59 falling short of the estimated -$33.83 by -11.11%.
SPRB Stock Performance
Access detailed SPRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
